Valneva SE (LON:0OB3)
4.203
-0.126 (-2.90%)
At close: Oct 20, 2025
Valneva SE Revenue
Valneva SE had revenue of 48.33M EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33M, up 25.47% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
196.33M EUR
Revenue Growth
+25.47%
P/S Ratio
3.73
Revenue / Employee
275.35K EUR
Employees
713
Market Cap
628.40M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
Hikma Pharmaceuticals | 2.35B |
ConvaTec Group | 1.72B |
Spire Healthcare Group | 1.55B |
Genus | 672.80M |
Valneva SE News
- 7 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 14 days ago - Valneva SE (VALN) Lowers 2025 Sales Forecast Amid Vaccine Setback - GuruFocus
- 15 days ago - Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing - Seeking Alpha
- 15 days ago - Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates - GlobeNewsWire
- 21 days ago - Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ - Nasdaq
- 21 days ago - Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 23 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - PRNewsWire
- 26 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN - GlobeNewsWire